• 
• 
• 

Our parallel throughput processes have two main stages:

Stage I involves parallel expression of multiple variants produced using site-directed mutagenesis in small quantities for rapid characterization and screening. For most customers, screening at stage I involves SDS-PAGE, analytical gel filtration and mass spectrometry. However, we will customize and/or scale Stage I to meet specific requirements:

• For biologics customers, we can tailor Stage I to produce multiple endotoxin-free proteins that can be used directly in cell-based and small animal screening
• For structure based drug design we will deliver necessary quantities of purified proteins for crystallization screening
  
  

Stage II involves the scaled-up production of protein variants selected from Stage I. Stage II is traditional scale-up and purification, but can be tailored to parallel production of multiple variants. This stage yields milligram to gram quantities of highly purified product.

Both Stage I and Stage II work in fixed time frames so that you can count on delivery of data and product to work within your project timelines.